Where There Is Conflict: Avandia Advisory Committee Waivers

Where There Is Conflict: Avandia Advisory Committee Waivers
Six participants have been granted conflict of interest waivers for the joint meeting of the FDA's Endocrinologic & Metabolic Drugs and the Drug Safety & Risk Management Advisory Committees' review of GlaxoSmithKline's Avandia on July 30.
Affiliation	Status at Avandia meeting	Type of Interest	Nature of Conflict	Magnitude of Conflict
John Teerlink, University of California - San Francisco	Temporary member	Blinded Endpoint Reviewer; Stock in a Health Sector Mutual Fund	Competing firm	From $10,001 to $50,000 per year; Stock valued at between $50,001 and $100,000
Thomas Pickering, Columbia University	Temporary member	Advisory Board; Stocks	Competing firms	Less than $10,001 per year; Stocks valued from $5,001 to $25,000 in aggregate
David Schade, University of New Mexico	Temporary member	Unrelated speaker's bureau; Unrelated Consulting	Competing firm	Less than $10,001 per year; Less than $10,001 per year
Morris Schambelan, San Francisco General Hospital	Temporary member	Member of Complications Committee	Competing firm	Less than $10,001 per year
Curt Furber, Wake Forest University	Non-voting temporary member	Drug Safety Monitoring Board	NIH-sponsored study also funded by GSK and two competing firms	Less than $10,001 per year
Steven Nissen, Cleveland Clinic	Non-voting consultant	Employer's Research Contracts/Grants	Competing firms	Two between $100,001 and $300,000; One greater than $300,000